Beijing Tide Pharmaceutical Co., Ltd.

Beijing University of Chemical Tehcnology

Peking University

Beijing Baidu Netcom Science Technology Co., Ltd

Beijing Aeronautical Science & Technology Research Institute, Commercial Aircraft Corporation of China

Yanan Liu

Liying Zhou

Yanping Zhao

Hongjun Wang

Yuanyuan Jiang

Jing Li

Gong Li

Kai Liu

Ning Shao

Yeming Wang

Fengping Xiao

Jianmei Pang

Weiting Zhong

Huai Huang

Zewang Feng

Jie Meng

Dianqing Li

Junting Feng

Xuelian Liu

Yufei He

Nana Tian

Yixin He

Xichao Chen

Shenzhen Fu

Ying Wang

Qian Wang

Jing Zhao

Dan Li

Yu Wang

Da Qu

Fajie Li

Yun Wu

Dalong Ma

Zhenguang Zou

Weina Liu

Yingmei Zhang

Wenling Han

Caihua Yin

Linjie Tian

Fengzhi Fu

Jiaxuan Fan

Xiaoxue Yue

CheungLing Cheng

Zhaolu Zhu

Di Lu

Minghao Zhu

Shugen Liu

Rongxin Feng

Chenxiao Liu

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

The present invention discloses a catalyst for in-situ CO2 capture and coupling reduction with biomass oxidation, a preparation method therefor and an application thereof. The catalyst is applied to the coupling reaction of photocatalytic CO2 reduction and biomass oxidation. The preparation of the catalyst is to synthesize layered double hydroxides (LDHs) containing CO32− between layers by using coprecipitation method, hydrothermal method, sol-gel method and the like, wherein the chemical formula is [M1−x2+Mx3+(OH)2]x+(An−)x/n·mH2O, which has a thickness of 20-30 nm and an average particle diameter of 60-90 nm. Then metal ion vacancy defects are produced on LDHs laminate by using a NaOH/KOH selective etching to obtain the corresponding catalyst. The catalyst is used in photocatalytic reaction, characterized in that CO32− is continuously consumed in the reaction process, and the catalyst can absorb CO2 in the air for recovery after the reaction, and can be repeatedly used to continuously consume CO2 in the air, thus realizing the direct capture and effective utilization of CO2.

Catalyst for COcapture and conversion coupling with biomass oxidation, a preparation method therefor and an application thereof

The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.

Method for treating fatty liver disease and/or steatohepatitis

The present invention relates to a salt of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-diamine and a solid form thereof, a method for preparing the solid form and a pharmaceutical composition comprising the solid form, as well as a use of the solid form for preventing or treating diseases modulated by P2X3 and/or P2X2/3 receptor antagonists.

Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof

The prevent disclosure provides a method and apparatus for adjusting a perspective of a direction indicator, an electronic device, and a storage medium, which includes that: a first area and a second area corresponding to a first direction indicator are acquired, where the first direction indicator is configured to indicate a forward direction in a panorama display scene, the first area is a visible area of the first direction indicator in a graphical user interface, and the second area is an invisible area of the first direction indicator outside the graphical user interface; an initial perspective range corresponding to the second area is acquired; a target perspective range to which a first perspective belongs is determined from the initial perspective range, and a second direction indicator corresponding to the target perspective range is displayed; and the first perspective is adjusted to a second perspective based on the second direction indicator.

Method and apparatus for adjusting perspective of direction indicator, electronic device, and storage medium

The present invention relates to a solid form of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-diamine or a hydrate thereof, a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and a use of the solid form for the prevention or treatment of a disease modulated by P2X3 and/or P2X2/3 receptor antagonists.

Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof

The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.

Double-stranded RNA molecule targeting CKIP-1 and use thereof

The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.

Pregabalin sustained release composition and method for preparing the same

P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

Cu/MMgOinterfacial catalyst for selective alkyne hydrogenation and its preparation method are disclosed. The preparation method of the catalyst includes: the mixture of salt and alkali solution is nucleated momentarily by nucleation/crystallization isolation method, preparing the composite metal hydroxide CuMMg-LDHs as precursor, which has typical hexagonal morphology of the double hydroxide; the precursor is topologically transformed by heat treatment to produce unsaturated oxide; the catalyst with Cu-MMgOinterface structure is prepared by separating and electronically modifying Cu particles. By adjusting the ratio of Cu/Min LDHs, the electronic and geometric structure of Cu-MMgOinterface can be flexibly controlled, thus enhancing the reaction activity, product selectivity and stability. The catalyst can be used in the selective hydrogenation of various alkynes in the fields of petrochemical and fine chemical industry, with the outstanding catalytic activity and C&#x2550;C double bond selectivity. The catalyst also has good reusability.

Cu/MMgOinterfacial catalyst for selective alkyne hydrogenation and its preparation method

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist. 

The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK). 

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK). 

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

Growing community of inventors

Beijing, China

Yanan Liu